最新发布
Guest article: Open-source education is key to helping agriculture overcome its data phobia
Editor’s note: Rob Ward is the CEO and cofounder of Vitagri Org Ltd, a UK agtech company building measurement and …
Biologicals Expansion Accelerates Globally — But Profitability Will Define the Winners
As the global biologicals market continues its rapid expansion, industry leaders say success will depend on far more than simply bringing products to market. During the recent webinar “Biological Expansions: How To Stay Competitive” hosted by AgriBusiness Global, experts explored how biological companies — and traditional crop protection manufacturers entering the segment — can stay competitive and profitable in an increasingly crowded marketplace.
Biologicals Expansion Accelerates Globally — But Profitability Will Define the Winners
As the global biologicals market continues its rapid expansion, industry leaders say success will depend on far more than simply bringing products to market. During the recent webinar “Biological Expansions: How To Stay Competitive” hosted by AgriBusiness Global, experts explored how biological companies — and traditional crop protection manufacturers entering the segment — can stay competitive and profitable in an increasingly crowded marketplace.
Skin and beauty drive growth in Kenvue’s Q1 results ahead of Kimberly-Clark deal
Kenvue has reported robust growth across sales, margins, and earnings in Q1 of 2026, with its Skin Health and Beauty division delivering the strongest performance as the company advances toward its planned acquisition by Kimberly-Clark.
Skin and beauty drive growth in Kenvue’s Q1 results ahead of Kimberly-Clark deal
Kenvue has reported robust growth across sales, margins, and earnings in Q1 of 2026, with its Skin Health and Beauty division delivering the strongest performance as the company advances toward its planned acquisition by Kimberly-Clark.
富美实获法院令,从巴西分销商Belagrícola扣押超2200万美元的谷物
大农化网报道:美国富美实获得了一项初步禁令,获准从巴西农业投入品分销商Belagrícola处扣押价值约 1.12亿雷亚尔(约合2260万美元)的谷物。此举进一步加大了该分销商的压力,后者正在寻求法院批准其庭外重组计划。 该争…
Danone Winds Down US Plant-Based Facility While Doubling Down on Conventional Dairy
Danone is closing its plant-based beverage facility in Bridgeton, New Jersey, with the site scheduled to cease operations on August 4. The closure will affect 114 employees, with layoffs running through November 2, according to a Worker Adjustment and Retraining Notification (WARN) filed with the state.
Danone Winds Down US Plant-Based Facility While Doubling Down on Conventional Dairy
Danone is closing its plant-based beverage facility in Bridgeton, New Jersey, with the site scheduled to cease operations on August 4. The closure will affect 114 employees, with layoffs running through November 2, according to a Worker Adjustment and Retraining Notification (WARN) filed with the state.
How HIV-1 Develops Resistance to Broadly Neutralizing Antibodies
One of the most challenging aspects of combatting HIV-1 infection is that the virus continually evades neutralizing antibodies. However, one consequence of this is that a small percentage of people with HIV-1 (1-5%) develop rare, broadly neutralizing antibodies (bNAbs) that can neutralize a large fraction of global HIV-1 isolates. These broadly neutralizing antibodies are among the most promising new long-acting HIV treatments, offering the potential to forego traditional daily dose of antiretroviral drugs. Indeed, a recent trial found that participants who received a single dose of two bNAbs maintained a nearly undetectable viral load for up to 20 weeks, and a third did so for about a year.
How HIV-1 Develops Resistance to Broadly Neutralizing Antibodies
One of the most challenging aspects of combatting HIV-1 infection is that the virus continually evades neutralizing antibodies. However, one consequence of this is that a small percentage of people with HIV-1 (1-5%) develop rare, broadly neutralizing antibodies (bNAbs) that can neutralize a large fraction of global HIV-1 isolates. These broadly neutralizing antibodies are among the most promising new long-acting HIV treatments, offering the potential to forego traditional daily dose of antiretroviral drugs. Indeed, a recent trial found that participants who received a single dose of two bNAbs maintained a nearly undetectable viral load for up to 20 weeks, and a third did so for about a year.
